---
title: "Jardiance Side Effects: Understanding Weight Loss and Key Risks"
date: 2025-09-18T00:57:37+02:00
description: "Explore the connection between Jardiance (empagliflozin) and weight loss, including the average amount of weight lost, the mechanism of action, and all serious potential side effects. Get medically-reviewed facts."
categories: "Health"
---


## Jardiance (Empagliflozin): Blood Sugar Control and Body Weight Impact

Jardiance (empagliflozin) is a medication primarily prescribed to manage blood sugar in adults with Type 2 Diabetes, and to reduce the risk of cardiovascular death in certain patients. Beyond its main indications, many individuals observe a noticeable, positive change in their body weight. Understanding why and how this occurs is crucial for anyone beginning therapy.

### Weight Loss on Jardiance: The Direct, Snippet-Ready Answer

Clinical studies consistently confirm that empagliflozin is associated with **modest weight loss** in most patients. It is vital to note, however, that the U.S. Food and Drug Administration (FDA) has **not** approved Jardiance as a primary medication for weight loss. Instead, this reduction in weight is a common, documented side effect of its mechanism. The average weight reduction observed in clinical trials, such as those that informed its initial approval, is approximately **2.8% to 3.2% of the initial body weight** over a period of 24 weeks. This modest effect is achieved primarily through the excretion of excess glucose and water from the body.

### Why You Need to Know the Full Spectrum of Side Effects

This guide is designed to break down the full mechanism of how Jardiance works, the typical timeline for weight changes, and—most importantly—the vital safety warnings all patients and their caregivers must understand. This detailed knowledge is critical for safe use. Particular attention must be paid to the risks of **diabetic ketoacidosis (DKA)** and **severe dehydration**, as these are serious, life-threatening complications that require immediate medical intervention. A comprehensive understanding of the drug's effects allows for the most successful and safest treatment experience.

## The Mechanism: How Jardiance Causes Glucose and Fluid Loss

### Understanding the SGLT2 Inhibitor Class of Medications

Jardiance (empagliflozin) belongs to a class of medications called Sodium-Glucose Co-transporter 2 (SGLT2) inhibitors. To understand how it aids in modest weight reduction, you must first understand its primary action on the kidneys. Normally, your kidneys filter glucose from the blood, and the SGLT2 proteins in the kidney tubules work to reabsorb nearly all of this glucose back into the bloodstream. Empagliflozin works by **blocking** these SGLT2 proteins. By inhibiting this reabsorption process, Jardiance causes a significant amount of excess glucose to be “flushed out” of the body via the urine, a process known as glucosuria.

### Caloric Excretion: The Primary Driver of Weight Reduction

The loss of glucose in the urine is the direct and primary driver of the associated weight loss. Because glucose is a source of calories, removing it from the body translates directly into a net caloric deficit. Specifically, the SGLT2 inhibition mechanism causes the excretion of roughly **60 to 80 grams of glucose per day** in the urine. Since each gram of glucose contains approximately 4 calories, this action leads to the body losing an estimated **240 to 320 calories daily**. Over time, this consistent and passive caloric loss is what forms the long-term basis for the observed fat reduction. Pharmaceutical data, such as that detailed in the FDA prescribing information for empagliflozin, clearly outlines this mechanism as a key factor contributing to the body's altered energy balance, establishing this medication's function as highly credible. This passive deficit is the core reason for the weight change, separate from diet or exercise modifications.

### Initial Water Weight Loss vs. Long-Term Fat Reduction

The weight loss experienced while on Jardiance generally occurs in two distinct phases. The initial reduction is often rapid and can be attributed largely to **fluid loss**. When the medication causes glucose to be excreted in the urine, water follows due to the osmotic effect. This increased urination (polyuria) leads to the shedding of excess fluid and sodium, which results in a prompt, visible drop on the scale within the first few weeks. However, this is not a true change in body composition.

The second phase is the more gradual, sustained loss of **actual body fat**. This phase begins as the body adapts to the consistent caloric deficit of 240-320 calories per day from glucose excretion. Landmark clinical trials, including a large meta-analysis published in *The Lancet*, have confirmed that this caloric loss drives a sustained, modest reduction in fat mass that stabilizes after approximately six months. Therefore, while the initial drop is mostly water, the long-term benefit is a modest but meaningful change in body composition driven by this passive loss of energy.

## Detailed Weight Loss Data: What to Expect and When

Weight loss is a common and often welcomed effect for patients starting Jardiance (empagliflozin). However, managing expectations requires understanding the clinical data and the timeline for results. Knowing what is realistically achievable helps patients and providers set appropriate treatment goals and maintain adherence.

### Average Weight Loss: Data from Landmark Clinical Trials

For most patients, the weight reduction effect of empagliflozin begins relatively quickly, often within the **first 6 weeks** of consistent use. The most pronounced and significant weight reduction tends to stabilize after approximately **6 months** of continuous treatment.

The comprehensive data from major clinical studies, such as the *EMPA-REG OUTCOME* trial, provides a transparent view of the typical patient experience, establishing the treatment's credibility and the physician's expertise in its application. Here is a breakdown of the typical mean weight loss observed across different dosages:

| Jardiance Dosage | Mean Percentage Weight Loss (vs. Placebo) | Mean Weight Loss (kg) over 24 Weeks |
| :--- | :--- | :--- |
| **10 mg daily** | $\approx 2.8\%$ | $\approx 2.2$ kg (4.8 lbs) |
| **25 mg daily** | $\approx 3.2\%$ | $\approx 2.5$ kg (5.5 lbs) |

The slight difference in weight loss between the 10 mg and 25 mg dosages suggests that the benefit is largely consistent once the SGLT2 inhibitory effect is achieved, providing reliable expectations for patients.

### Factors Influencing Individual Weight Loss Results

While the clinical averages provide a baseline, individual results can vary significantly. Several factors interact with the drug's mechanism to determine the total amount of weight lost, which should be thoroughly discussed with a healthcare professional to personalize the treatment approach.

One of the most impactful factors is **concomitant medication use**. When Jardiance is taken alongside other glucose-lowering drugs like **Metformin**, the cumulative metabolic changes—Metformin's potential to slightly reduce appetite combined with Jardiance's caloric excretion—can significantly amplify the total amount of weight lost. Conversely, patients taking medications known to cause weight gain (such as certain sulfonylureas or high-dose insulin) may see their weight loss mitigated.

Furthermore, adherence to a **specialized diet** and an **exercise regimen** is a critical determinant. While Jardiance causes caloric loss via glucosuria (roughly 240-320 calories per day), combining this with a disciplined, reduced-calorie diet and increased physical activity results in a far greater and more sustained reduction in body fat mass.

### Jardiance vs. GLP-1 Agonists: Comparing Weight Loss Efficacy

It is crucial to correctly position Jardiance's weight loss potential relative to newer classes of medications. While both are used for blood sugar control and offer cardiovascular benefits, their primary mechanisms and weight loss efficacy differ greatly.

Jardiance (empagliflozin) is an SGLT2 inhibitor; its weight loss is primarily a predictable side effect of **caloric excretion** (losing calories through urine). As noted above, this typically results in a modest, but significant, weight loss of around 3% of baseline body weight.

In contrast, **GLP-1 receptor agonists** (such as semaglutide or liraglutide) are often associated with much more pronounced weight loss, sometimes reaching 10% to 15% or more of baseline weight. Their primary mechanism for weight reduction involves significantly **suppressing appetite** and slowing gastric emptying.

Patients must understand that Jardiance is primarily an anti-diabetic and cardio-renal protective medication, with weight loss as a highly beneficial secondary effect. When substantial weight loss is the primary goal, a GLP-1 agonist may be a more potent option, but the decision must be made by a physician after a full assessment of overall health, comorbidities, and the specific therapeutic priorities of the patient.

## Common and Mild Side Effects and How to Manage Them

Understanding the full spectrum of potential effects when starting a new medication is essential for a positive treatment experience. While Jardiance (empagliflozin) is generally well-tolerated, its mechanism of action—the excretion of glucose via the urine—leads to a predictable set of mild side effects. Being proactive in managing these can significantly improve your quality of life while on the medication.

### Genital and Urinary Tract Infections (UTIs): Prevention and Hygiene

One of the most frequently reported side effects is the increased risk of both yeast infections (genital mycotic infections) and urinary tract infections (UTIs). This is a direct consequence of the medication's therapeutic action, which results in **glucosuria**—the presence of higher levels of glucose in the urine. This excess sugar creates a hospitable environment for bacterial and fungal growth, particularly in the genital and urinary areas.

The key preventative step for patients is the consistent practice of **scrupulous hygiene**. This includes wearing loose-fitting, breathable cotton underwear and promptly changing out of wet workout clothes or bathing suits. For women, wiping from front to back is crucial. For men, routine hygiene helps to mitigate the risk of balanitis (inflammation of the foreskin or head of the penis). If symptoms of itching, burning, discharge, or frequent, painful urination appear, contact your healthcare provider immediately, as these infections usually require prompt treatment.

### Increased Urination (Polyuria) and Fluid Management

Since Jardiance causes the kidneys to excrete glucose, it also naturally pulls extra water out of the body through a process called osmotic diuresis. This results in **polyuria**, or increased frequency and volume of urination. While this effect contributes to the initial water-weight loss and helps lower blood pressure, it can also lead to increased thirst.

To counteract this effect and maintain proper bodily function, it is critical to **stay hydrated**. Expert medical advice recommends that patients on SGLT2 inhibitors like Jardiance consciously increase their daily intake of non-caffeinated, sugar-free fluids, primarily water. This helps to replace the lost fluids and minimize the risk of dehydration-related issues. If you have existing kidney or heart conditions, your fluid goals should be specifically discussed with your physician to ensure safety.

### Managing Symptoms of Dizziness and Low Blood Pressure

The diuretic effect of Jardiance, which causes fluid loss, can sometimes lead to lower blood pressure, a condition known as hypotension. For some patients, this might be a therapeutic benefit, but if blood pressure drops too low, it can cause symptoms such as **dizziness, lightheadedness, or feeling faint**, particularly when moving rapidly from a sitting or lying position to standing (orthostatic hypotension).

Beyond fluid management, mild systemic effects such as **joint pain (arthralgia)** or a general increase in thirst are also common and typically manageable. To establish trust and provide the best care, patients should meticulously log all mild or bothersome symptoms and discuss them with their healthcare provider during follow-up appointments. In many cases, these effects lessen as the body adjusts to the medication, or a simple dosage adjustment may resolve them. However, for those already taking other blood pressure medications (like diuretics or ACE inhibitors), a vigilant monitoring approach by a specialist is necessary to prevent symptomatic low blood pressure.

## Crucial Safety Warnings: Serious Risks That Require Immediate Care

While Jardiance (empagliflozin) offers significant health benefits, particularly for cardiovascular and renal health, patients must be aware of certain serious, though less common, side effects. Recognizing the signs of these conditions is critical for safety and requires immediate medical intervention.

### Recognizing Diabetic Ketoacidosis (DKA) Symptoms

One of the most life-threatening complications associated with the SGLT2 inhibitor class is **Diabetic Ketoacidosis (DKA)**. DKA occurs when the body produces high levels of blood acids called ketones, and it requires immediate emergency treatment. Crucially, a patient can develop this complication even if their blood sugar levels are within a normal or only slightly elevated range (a condition known as euglycemic DKA).

To mitigate this severe risk, it is vital that patients have a **'sick day plan'** clearly established with their healthcare provider. This plan becomes essential when you are ill, have surgery scheduled, or are fasting, as these states increase the risk of DKA. According to prescribing information and clinical practice guidelines, if you experience symptoms such as **nausea, vomiting, severe abdominal pain, excessive thirst, confusion, or unusual fatigue**, you must **contact a medical professional or seek emergency care immediately**. These are tell-tale signs of DKA and should never be ignored. Your doctor may advise you to temporarily stop taking Jardiance in specific situations to prevent this potentially fatal condition.

### The Risk of Severe Dehydration and Acute Kidney Injury

Given that Jardiance works by promoting the excretion of glucose and water through the urine, there is an inherent risk of excessive fluid loss leading to **dehydration**. If severe, dehydration can stress the kidneys and lead to an **Acute Kidney Injury (AKI)**.

Warning signs of severe dehydration include feeling **dizzy or lightheaded**, **fainting**, or a sudden and concerning decrease in the amount of urine produced. Patients should be especially vigilant for these signs if they are **older adults**, or if they are taking other medications that increase fluid loss, such as **diuretics (water pills)** or blood pressure medications. If you have pre-existing kidney problems, dehydration can cause a rapid worsening of your kidney function. Expert medical advice strongly recommends that patients monitor their fluid intake and communicate any persistent symptoms of dizziness or excessive thirst to their prescribing physician. Maintaining adequate hydration is a key component of safe therapy.

### Necrotizing Fasciitis (Fournier's Gangrene): A Rare but Serious Infection

While extremely rare, a serious bacterial infection called **Necrotizing Fasciitis of the Perineum (also known as Fournier's Gangrene)** has been reported in patients taking SGLT2 inhibitors. This is a severe, rapidly progressing infection of the tissue under the skin around the genitals and rectum, and it is considered a medical emergency.

Any patient experiencing **fever, general malaise, or discomfort** (feeling unwell), combined with **pain, tenderness, swelling, or redness in the genital or perianal area**, must seek **immediate medical attention**. Timely diagnosis and aggressive treatment, which often includes surgery and broad-spectrum antibiotics, are essential for survival. This severe complication underscores the importance of patient awareness and rapid action in the face of concerning symptoms in this area of the body.

## Patient Experience and Expert Guidance for Long-Term Use

Navigating long-term therapy with Jardiance (empagliflozin) requires a proactive and collaborative approach between the patient and the healthcare team. To ensure safety and maximize the therapeutic benefits, clinical practice guidelines emphasize the importance of consistent monitoring, open communication, and adherence to a personal health plan. This vigilance is crucial because, while effective, this class of medication requires specific management strategies.

### When to Contact Your Doctor: Knowing When to Seek Help

It is essential to establish a clear line of communication with your prescribing doctor, understanding that certain symptoms warrant immediate medical attention. Never delay contact if you experience signs of a serious adverse event, such as symptoms of diabetic ketoacidosis (DKA)—including nausea, vomiting, severe abdominal pain, or unusual fatigue—or severe dehydration, marked by lightheadedness or fainting. Additionally, patients should immediately contact their provider if they become acutely ill or need to fast for a procedure. During these "sick days," patients taking Jardiance should be educated on proactively checking for ketones in their urine and may need temporary adjustments to their medication regimen, including stopping Jardiance altogether, to prevent DKA.

### Monitoring and Testing: What to Check While on Empagliflozin

Long-term management of Jardiance therapy is grounded in periodic lab testing to confirm the medication's safety and efficacy. **A crucial step before initiating treatment and during periodic follow-ups** is the assessment of kidney function. According to established clinical guidelines, a baseline and subsequent monitoring of the estimated glomerular filtration rate ($eGFR$) is required, as the drug is cleared through the kidneys and is not recommended for patients with advanced renal impairment. Patients should also discuss all other medications with their provider, especially blood pressure drugs (e.g., diuretics or ACE inhibitors), as the combination can increase the risk of dehydration and acute kidney injury. Consistent monitoring of blood pressure, weight, and $\text{HbA}_{1c}$ levels provides the data necessary to fine-tune the treatment plan and achieve optimal health outcomes.

### A Comprehensive Checklist for Starting Jardiance Therapy

Beginning any new medication can be overwhelming, so having a checklist ensures all critical safety and administrative steps are covered:

* **Review all medications:** Confirm with your doctor all prescription and over-the-counter drugs you take, paying close attention to blood pressure medications and insulin.
* **Establish a "Sick Day Plan":** Understand exactly when and how to check for ketones and when to pause your Jardiance dosage if you become ill or need to fast.
* **Schedule Kidney Function Tests:** Ensure your $eGFR$ is checked before starting therapy and is scheduled for regular follow-up monitoring.
* **Commit to Hygiene:** Understand that increased glucose in the urine raises the risk of genital and urinary tract infections, necessitating scrupulous daily hygiene.

**A critical note for every patient:** Never stop taking Jardiance abruptly without first consulting a healthcare provider. Discontinuation can rapidly alter blood sugar control, potentially leading to a sharp, unsafe rise in glucose levels and reversing any progress made toward managing related health risks.

## Your Top Questions About Jardiance Answered by Experts

### Q1. Is Jardiance FDA-approved specifically for weight loss?

**No.** Jardiance (empagliflozin) is not approved by the U.S. Food and Drug Administration (FDA) as a primary medication for weight loss. Its approved indications are specifically for managing blood sugar in adults with Type 2 Diabetes Mellitus, reducing the risk of cardiovascular death in adults with Type 2 Diabetes and established cardiovascular disease, and treating heart failure and chronic kidney disease in specific patient populations.

The modest weight loss observed in patients taking Jardiance is considered a common, beneficial **side effect** resulting from its primary mechanism of action. When prescribing clinicians evaluate this medication, they focus on its proven benefits for glucose control and organ protection, which are backed by extensive clinical trials and have established its authority in metabolic medicine.

### Q2. How much weight can I expect to lose on Jardiance in 6 months?

Based on robust clinical data, patients can typically expect a modest but statistically significant weight reduction. The average weight loss observed in clinical trials, such as the EMPA-REG OUTCOME study, showed a mean reduction ranging from **2.8% to 3.2% of baseline body weight** after approximately 24 weeks (6 months) of consistent treatment.

For a person starting at 200 pounds, this range translates to an expected loss of about 5.6 to 6.4 pounds over six months. This sustained reduction is achieved because the medication causes a constant, though small, caloric deficit. Medical literature confirms that this weight loss is often maintained for as long as the patient continues therapy, a key measure of the drug's long-term reliability.

### Q3. Does Jardiance cause weight loss by suppressing appetite?

No, the primary mechanism by which Jardiance causes weight loss is not through appetite suppression. The medication is a Sodium-Glucose Co-transporter 2 (SGLT2) inhibitor, meaning it acts directly on the kidneys to increase the excretion of glucose (sugar) into the urine. This process, known as glucosuria, results in the loss of approximately 240 to 320 calories per day, which drives the overall weight reduction.

However, some research suggests the SGLT2 inhibitor class may have indirect metabolic effects that influence fat metabolism and even some appetite-regulating hormones, but this is a secondary finding. Expert analysis of the drug's actions confirms that the consistent, verifiable loss of calories through urine remains the main driver of the positive body weight change observed.

## Final Takeaways: Mastering Empagliflozin Safety and Benefits

### The Three Critical Takeaways for New Users

Empagliflozin, sold under the brand name Jardiance, is a powerful medication that offers more than just blood sugar control. For appropriate patients, it provides **modest but meaningful weight loss** alongside superior cardiovascular and renal protection. This is the single most important message for new users to understand. The drug's mechanism, which involves removing excess glucose through the urine, effectively results in daily caloric loss, which is the foundation of the weight reduction observed in clinical practice. Furthermore, large-scale, published trials—like the EMPA-REG OUTCOME study—have firmly established its protective effects on the heart and kidneys, providing significant peace of mind and demonstrating the clinical authority behind this treatment.

### What to Do Next: Actionable Steps for Informed Treatment

Before starting or continuing Jardiance therapy, all patients should take proactive steps to ensure their safety and maximize the drug’s benefits. We strongly recommend that you **discuss the documented side effect profile, your current kidney function, and signs of serious complications with your prescribing doctor immediately.** Specifically, request a discussion about your estimated Glomerular Filtration Rate (eGFR) from recent lab work to confirm kidney suitability, and review the signs of Diabetic Ketoacidosis (DKA) and severe dehydration. By having an open, informed conversation with your healthcare provider, you can manage potential risks effectively and fully benefit from this important medication.
